The global cancer monoclonal antibodies market size accounted for USD 105.55 billion in 2024, grew to USD 125.10 billion in 2025 and is expected to be worth around USD 577.26 billion by 2034, registering a CAGR of 18.52% between 2024 and 2034. The North America cancer monoclonal antibodies market size is calculated at USD 41.16 billion in 2024 and is estimated to grow at a CAGR of 18.67% during the forecast period.
1.1. Research Objective
1.2. Scope of the Study
1.3. Definition
2.1. Research Approach
2.2. Data Sources
2.3. Assumptions & Limitations
3.1. Market Snapshot
4.1. Introduction
4.2. Market Classification and Scope
4.3. Industry Value Chain Analysis
4.3.1. Raw Material Procurement Analysis
4.3.2. Sales and Distribution Channel Analysis
4.3.3. Downstream Buyer Analysis
5.1. COVID-19 Landscape: Cancer Monoclonal Antibodies Industry Impact
5.2. COVID 19 - Impact Assessment for the Industry
5.3. COVID 19 Impact: Global Major Government Policy
5.4. Market Trends and Opportunities in the COVID-19 Landscape
6.1. Market Dynamics
6.1.1. Market Drivers
6.1.2. Market Restraints
6.1.3. Market Opportunities
6.2. Porter’s Five Forces Analysis
6.2.1. Bargaining power of suppliers
6.2.2. Bargaining power of buyers
6.2.3. Threat of substitute
6.2.4. Threat of new entrants
6.2.5. Degree of competition
7.1.1. Company Market Share/Positioning Analysis
7.1.2. Key Strategies Adopted by Players
7.1.3. Vendor Landscape
7.1.3.1. List of Suppliers
7.1.3.2. List of Buyers
8.1. Cancer Monoclonal Antibodies Market, by Type, 2024-2034
8.1.1. Humanized
8.1.1.1. Market Revenue and Forecast (2021-2034)
8.1.2. Human
8.1.2.1. Market Revenue and Forecast (2021-2034)
8.1.3. Chimeric
8.1.3.1. Market Revenue and Forecast (2021-2034)
8.1.4. Murine
8.1.4.1. Market Revenue and Forecast (2021-2034)
9.1. Cancer Monoclonal Antibodies Market, by Application, 2024-2034
9.1.1. Blood Cancer
9.1.1.1. Market Revenue and Forecast (2021-2034)
9.1.2. Breast Cancer
9.1.2.1. Market Revenue and Forecast (2021-2034)
9.1.3. Lung Cancer
9.1.3.1. Market Revenue and Forecast (2021-2034)
9.1.4. Melanoma
9.1.4.1. Market Revenue and Forecast (2021-2034)
9.1.5. Colorectal Cancer
9.1.5.1. Market Revenue and Forecast (2021-2034)
9.1.6. Liver Cancer
9.1.6.1. Market Revenue and Forecast (2021-2034)
9.1.7. Others
9.1.7.1. Market Revenue and Forecast (2021-2034)
10.1. Cancer Monoclonal Antibodies Market, by Monoclonal Antibody Therapies, 2024-2034
10.1.1. Bevacizumab (Avastin)
10.1.1.1. Market Revenue and Forecast (2021-2034)
10.1.2. Rituximab (Rituxan)
10.1.2.1. Market Revenue and Forecast (2021-2034)
10.1.3. Trastuzumab (Herceptin)
10.1.3.1. Market Revenue and Forecast (2021-2034)
10.1.4. Cetuximab (Erbitux)
10.1.4.1. Market Revenue and Forecast (2021-2034)
10.1.5. Panitumumab (Vectibix)
10.1.5.1. Market Revenue and Forecast (2021-2034)
10.1.6. Other Monoclonal Antibody Therapies
10.1.6.1. Market Revenue and Forecast (2021-2034)
11.1. Cancer Monoclonal Antibodies Market, by End-User, 2024-2034
11.1.1. Hospitals
11.1.1.1. Market Revenue and Forecast (2021-2034)
11.1.2. Research Institutes
11.1.2.1. Market Revenue and Forecast (2021-2034)
11.1.3. Others
11.1.3.1. Market Revenue and Forecast (2021-2034)
12.1. North America
12.1.1. Market Revenue and Forecast, by Type (2021-2034)
12.1.2. Market Revenue and Forecast, by Application (2021-2034)
12.1.3. Market Revenue and Forecast, by Monoclonal Antibody Therapies (2021-2034)
12.1.4. Market Revenue and Forecast, by End-User (2021-2034)
12.1.5. U.S.
12.1.5.1. Market Revenue and Forecast, by Type (2021-2034)
12.1.5.2. Market Revenue and Forecast, by Application (2021-2034)
12.1.5.3. Market Revenue and Forecast, by Monoclonal Antibody Therapies (2021-2034)
12.1.5.4. Market Revenue and Forecast, by End-User (2021-2034)
12.1.6. Rest of North America
12.1.6.1. Market Revenue and Forecast, by Type (2021-2034)
12.1.6.2. Market Revenue and Forecast, by Application (2021-2034)
12.1.6.3. Market Revenue and Forecast, by Monoclonal Antibody Therapies (2021-2034)
12.1.6.4. Market Revenue and Forecast, by End-User (2021-2034)
12.2. Europe
12.2.1. Market Revenue and Forecast, by Type (2021-2034)
12.2.2. Market Revenue and Forecast, by Application (2021-2034)
12.2.3. Market Revenue and Forecast, by Monoclonal Antibody Therapies (2021-2034)
12.2.4. Market Revenue and Forecast, by End-User (2021-2034)
12.2.5. UK
12.2.5.1. Market Revenue and Forecast, by Type (2021-2034)
12.2.5.2. Market Revenue and Forecast, by Application (2021-2034)
12.2.5.3. Market Revenue and Forecast, by Monoclonal Antibody Therapies (2021-2034)
12.2.5.4. Market Revenue and Forecast, by End-User (2021-2034)
12.2.6. Germany
12.2.6.1. Market Revenue and Forecast, by Type (2021-2034)
12.2.6.2. Market Revenue and Forecast, by Application (2021-2034)
12.2.6.3. Market Revenue and Forecast, by Monoclonal Antibody Therapies (2021-2034)
12.2.6.4. Market Revenue and Forecast, by End-User (2021-2034)
12.2.7. France
12.2.7.1. Market Revenue and Forecast, by Type (2021-2034)
12.2.7.2. Market Revenue and Forecast, by Application (2021-2034)
12.2.7.3. Market Revenue and Forecast, by Monoclonal Antibody Therapies (2021-2034)
12.2.7.4. Market Revenue and Forecast, by End-User (2021-2034)
12.2.8. Rest of Europe
12.2.8.1. Market Revenue and Forecast, by Type (2021-2034)
12.2.8.2. Market Revenue and Forecast, by Application (2021-2034)
12.2.8.3. Market Revenue and Forecast, by Monoclonal Antibody Therapies (2021-2034)
12.2.8.4. Market Revenue and Forecast, by End-User (2021-2034)
12.3. APAC
12.3.1. Market Revenue and Forecast, by Type (2021-2034)
12.3.2. Market Revenue and Forecast, by Application (2021-2034)
12.3.3. Market Revenue and Forecast, by Monoclonal Antibody Therapies (2021-2034)
12.3.4. Market Revenue and Forecast, by End-User (2021-2034)
12.3.5. India
12.3.5.1. Market Revenue and Forecast, by Type (2021-2034)
12.3.5.2. Market Revenue and Forecast, by Application (2021-2034)
12.3.5.3. Market Revenue and Forecast, by Monoclonal Antibody Therapies (2021-2034)
12.3.5.4. Market Revenue and Forecast, by End-User (2021-2034)
12.3.6. China
12.3.6.1. Market Revenue and Forecast, by Type (2021-2034)
12.3.6.2. Market Revenue and Forecast, by Application (2021-2034)
12.3.6.3. Market Revenue and Forecast, by Monoclonal Antibody Therapies (2021-2034)
12.3.6.4. Market Revenue and Forecast, by End-User (2021-2034)
12.3.7. Japan
12.3.7.1. Market Revenue and Forecast, by Type (2021-2034)
12.3.7.2. Market Revenue and Forecast, by Application (2021-2034)
12.3.7.3. Market Revenue and Forecast, by Monoclonal Antibody Therapies (2021-2034)
12.3.7.4. Market Revenue and Forecast, by End-User (2021-2034)
12.3.8. Rest of APAC
12.3.8.1. Market Revenue and Forecast, by Type (2021-2034)
12.3.8.2. Market Revenue and Forecast, by Application (2021-2034)
12.3.8.3. Market Revenue and Forecast, by Monoclonal Antibody Therapies (2021-2034)
12.3.8.4. Market Revenue and Forecast, by End-User (2021-2034)
12.4. MEA
12.4.1. Market Revenue and Forecast, by Type (2021-2034)
12.4.2. Market Revenue and Forecast, by Application (2021-2034)
12.4.3. Market Revenue and Forecast, by Monoclonal Antibody Therapies (2021-2034)
12.4.4. Market Revenue and Forecast, by End-User (2021-2034)
12.4.5. GCC
12.4.5.1. Market Revenue and Forecast, by Type (2021-2034)
12.4.5.2. Market Revenue and Forecast, by Application (2021-2034)
12.4.5.3. Market Revenue and Forecast, by Monoclonal Antibody Therapies (2021-2034)
12.4.5.4. Market Revenue and Forecast, by End-User (2021-2034)
12.4.6. North Africa
12.4.6.1. Market Revenue and Forecast, by Type (2021-2034)
12.4.6.2. Market Revenue and Forecast, by Application (2021-2034)
12.4.6.3. Market Revenue and Forecast, by Monoclonal Antibody Therapies (2021-2034)
12.4.6.4. Market Revenue and Forecast, by End-User (2021-2034)
12.4.7. South Africa
12.4.7.1. Market Revenue and Forecast, by Type (2021-2034)
12.4.7.2. Market Revenue and Forecast, by Application (2021-2034)
12.4.7.3. Market Revenue and Forecast, by Monoclonal Antibody Therapies (2021-2034)
12.4.7.4. Market Revenue and Forecast, by End-User (2021-2034)
12.4.8. Rest of MEA
12.4.8.1. Market Revenue and Forecast, by Type (2021-2034)
12.4.8.2. Market Revenue and Forecast, by Application (2021-2034)
12.4.8.3. Market Revenue and Forecast, by Monoclonal Antibody Therapies (2021-2034)
12.4.8.4. Market Revenue and Forecast, by End-User (2021-2034)
12.5. Latin America
12.5.1. Market Revenue and Forecast, by Type (2021-2034)
12.5.2. Market Revenue and Forecast, by Application (2021-2034)
12.5.3. Market Revenue and Forecast, by Monoclonal Antibody Therapies (2021-2034)
12.5.4. Market Revenue and Forecast, by End-User (2021-2034)
12.5.5. Brazil
12.5.5.1. Market Revenue and Forecast, by Type (2021-2034)
12.5.5.2. Market Revenue and Forecast, by Application (2021-2034)
12.5.5.3. Market Revenue and Forecast, by Monoclonal Antibody Therapies (2021-2034)
12.5.5.4. Market Revenue and Forecast, by End-User (2021-2034)
12.5.6. Rest of LATAM
12.5.6.1. Market Revenue and Forecast, by Type (2021-2034)
12.5.6.2. Market Revenue and Forecast, by Application (2021-2034)
12.5.6.3. Market Revenue and Forecast, by Monoclonal Antibody Therapies (2021-2034)
12.5.6.4. Market Revenue and Forecast, by End-User (2021-2034)
13.1. Amgen Inc
13.1.1. Company Overview
13.1.2. Product Offerings
13.1.3. Financial Performance
13.1.4. Recent Initiatives
13.2. Eli Lilly and Company
13.2.1. Company Overview
13.2.2. Product Offerings
13.2.3. Financial Performance
13.2.4. Recent Initiatives
13.3. Merck & Co., Inc
13.3.1. Company Overview
13.3.2. Product Offerings
13.3.3. Financial Performance
13.3.4. Recent Initiatives
13.4. Novartis AG
13.4.1. Company Overview
13.4.2. Product Offerings
13.4.3. Financial Performance
13.4.4. Recent Initiatives
13.5. F. Hoffmann-La Roche Ltd.
13.5.1. Company Overview
13.5.2. Product Offerings
13.5.3. Financial Performance
13.5.4. Recent Initiatives
13.6. Bristol Myers Squibb Co.
13.6.1. Company Overview
13.6.2. Product Offerings
13.6.3. Financial Performance
13.6.4. Recent Initiatives
13.7. GlaxoSmithKline plc
13.7.1. Company Overview
13.7.2. Product Offerings
13.7.3. Financial Performance
13.7.4. Recent Initiatives
13.8. Johnson & Johnson
13.8.1. Company Overview
13.8.2. Product Offerings
13.8.3. Financial Performance
13.8.4. Recent Initiatives
13.9. AstraZeneca plc
13.9.1. Company Overview
13.9.2. Product Offerings
13.9.3. Financial Performance
13.9.4. Recent Initiatives
13.10. AbbVie
13.10.1. Company Overview
13.10.2. Product Offerings
13.10.3. Financial Performance
13.10.4. Recent Initiatives
14.1. Primary Research
14.2. Secondary Research
14.3. Assumptions
15.1. About Us
15.2. Glossary of Terms
No cookie-cutter, only authentic analysis – take the 1st step to become a Precedence Research client
Report Description
Get a Sample